This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TCF7L1 / Transcription factor 7-like 1 · Western blot design guide
Design a Western Blot for TCF7L1
Source-linked TCF7L1 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-TCF7L1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
TCF7L1 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~62.6 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | — | |
| Caveat | — | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Source-Linked TCF7L1 Western Blot Protocol Options
The M05152 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | A431 cell lysate (catalog M05152) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | M05152; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected TCF7L1 Western Blot Band Size?
TCF7L1 has a predicted mass of 62.6 kDa; no empirical band is supplied, and its nuclear location does not establish a migration shift.
| Single band near 62.6 kDa | Consistent with the predicted TCF7L1 mass; confirm identity with controls |
| Band near 62.6 kDa in a nuclear fraction | Consistent with TCF7L1's nuclear location; confirm identity with controls |
| Little signal in a cytoplasmic fraction | Consistent with TCF7L1's nuclear location |
| Additional bands at other sizes | Their identity is not established by the supplied features |
💡Expected TCF7L1 appearanceUniProt predicts 62.6 kDa for TCF7L1; no empirical band size is supplied, so use antibody and sample controls to identify any band near that size.
| UniProt predicted mass | Sets a 62.6 kDa reference for the intact protein |
| Calculated molecular weight | The supplied 62,631 Da value rounds to 62.6 kDa |
| Predicted intact protein mass | Does not establish an empirical migration position |
| Predicted mass reference | Provides a comparison point for bands above or below 62.6 kDa |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Nuclear TCF7L1 may be poorly recovered in the tested preparation | Check nuclear extraction and a positive control |
| Band higher than expected | The supplied features do not establish the cause | Verify identity with an independent antibody or TCF7L1 depletion |
| Band lower than expected | The supplied features do not establish the cause | Verify identity with an independent antibody or TCF7L1 depletion |
| Multiple bands | The supplied features do not establish distinct TCF7L1 bands | Compare bands with TCF7L1 depletion and antibody controls |
| Weak or no signal | Low target recovery or limited assay sensitivity | Check nuclear recovery, loading, and a positive control |
Experiment evidence
Western blot images showing TCF7L1 band
M05152 · TCF7L1
PB9897 · TCF7L1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for TCF7L1 Western blot
🧪For positive controls for TCF7L1 in Western blot, you can use no HPA-supported tissue or cell sample because none is provided.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: HPA provides no expression data, so tissue controls cannot be validated; a knockdown or KO line can provide a negative control.
HPA tissue expression evidence for TCF7L1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced TCF7L1 Western Blot Tips
Deeper troubleshooting and optimisation questions for TCF7L1, answered from its protein features.
Where should the TCF7L1 band appear?
Band shift · The predicted mass is 62.6 kDa. Use that as a reference when examining the blot; no empirical apparent band position was supplied, so an exact migration position cannot be established.
Can annotated isoforms explain multiple TCF7L1 bands?
Isoforms · Only one isoform is listed, with no alternative sequence supplied. The supplied features therefore do not identify an isoform-based explanation for multiple bands.
Do annotated modifications explain a shifted TCF7L1 band?
PTM · No modified residues or glycosylation sites are listed. The supplied features do not establish a modification-based shift, and a difference from 62.6 kDa alone would not identify its cause.
Does this guide establish induction of TCF7L1?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for TCF7L1?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the M05152 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should TCF7L1 signal be quantified across samples?
Quantitation · Compare samples using the same fraction and loading basis, especially if using nuclear extracts. Its nuclear localization makes fraction consistency important; the supplied features do not establish how TCF7L1 abundance changes between conditions.
Which sample fraction is most relevant for detecting TCF7L1?
Interpretation · TCF7L1 is annotated as nuclear. A nuclear-enriched sample is relevant when checking for its signal; interpret a weak whole-cell signal in light of that localization.
TCF7L1 is reported to form a stable complex with CTNNB1, but that interaction does not by itself establish a higher apparent mass for TCF7L1 on a Western blot. Assess any extra band separately against the 62.6 kDa prediction.
Start with the 62.6 kDa predicted mass and the annotated nuclear localization. The supplied record lists one isoform and no modified residues or glycosylation sites, so it does not assign an identity or cause to additional bands.
TCF7L1 is reported to form a stable complex with CTNNB1, but that interaction does not by itself establish a higher apparent mass for TCF7L1 on a Western blot. Assess any extra band separately against the 62.6 kDa prediction.
Start with the 62.6 kDa predicted mass and the annotated nuclear localization. The supplied record lists one isoform and no modified residues or glycosylation sites, so it does not assign an identity or cause to additional bands.
Boster reagents
TCF7L1 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-TCF3 TCF7L1 Rabbit Monoclonal Antibody
Cat # M05152
Real WB data
Anti-TCF7L1 Antibody Picoband®
Cat # PB9897
Two human-reactive the supplier antibodies have WB images: M05152 in A431 lysate and PB9897 in COLO320 whole-cell lysate. PB9897's caption reports a band near the expected 63 kDa. These examples do not establish performance in other samples or species.
Which to pick: Choose M05152 if its A431 lysate example matches your work, or PB9897 for a detailed COLO320 protocol with a reported 63 kDa band. Both list human reactivity; the supplied evidence does not establish which performs better.
Source: BosterBio TCF7L1 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q9HCS4.
- Human Protein Atlas. TCF7L1 tissue expression.
- PMC10643375 — target-verified WB comparison
- PMC10874473 — target-verified WB comparison
- PMC11139868 — target-verified WB comparison